NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. Portfolio company, NASDAQ-listed PDS Biotechnology (PDSB), in which NSCI holds a 4.72% equity stake, and which is developing novel cancer immunotherapies and infectious disease vaccines, reported (27 January 2021) that preclinical studies of its universal flu vaccine candidate PDS0202 have demonstrated early but promising efficacy against multiple influenza virus strains.
28 Jan 2022
WH Ireland: NetScientific (NSCI) - Portfolio company PDS Biotechnology announces preclinical data for its universal flu vaccine – effective against multiple influenza virus strains
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: NetScientific (NSCI) - Portfolio company PDS Biotechnology announces preclinical data for its universal flu vaccine – effective against multiple influenza virus strains
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
28 Jan 2022 -
Author:
Matthew Davis | Emma Ulker -
Pages:
5
NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. Portfolio company, NASDAQ-listed PDS Biotechnology (PDSB), in which NSCI holds a 4.72% equity stake, and which is developing novel cancer immunotherapies and infectious disease vaccines, reported (27 January 2021) that preclinical studies of its universal flu vaccine candidate PDS0202 have demonstrated early but promising efficacy against multiple influenza virus strains.